|Articles|June 15, 2004

Topical cyclosporine can handle more than dry-eye disease

Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME